Philips successfully prices offering of Notes for EUR 500 million to be used for repayment of existing debt, resulting in a debt-neutral effect - Seite 3
Relevant stabilisation regulations including FCA/ICMA apply.
MiFID II and UK MiFIR professionals/ECPs-only/No PRIIPs or UK PRIIPs KID
Manufacturer target market (MIFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information
document (KID) has been prepared as not available to retail in EEA or UK.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric
innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and
their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise
informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
Lesen Sie auch
Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips
with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic
business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many
factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.